Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTYP01 in Early Symptomatic Alzheimer's Disease
NCT07252440Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FAB122 in Alzheimer's disease (AD). Started Dec 2025; status: recruiting.
02
Drugs
FAB122
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07252440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252440.